Drug intelligence / Profile preview

Bensal HP

Development stage: Unknown
Lead developer: SMG Pharmaceuticals
Modality: Small Molecules
Administration: Topical

Overview

Bensal HP is a topical ointment indicated for the treatment of various dermatological conditions, including dermatitis, pyoderma, and excoriated skin that is slow to heal or vulnerable to infection. It is a combination product containing benzoic acid (6%) and salicylic acid (3%) in a base that includes oak bark extract. Salicylic acid functions as a keratolytic agent, promoting the desquamation of the stratum corneum by solubilizing intercellular cement, while benzoic acid provides antiseptic and antifungal properties. The formulation is designed to manage inflammation, prevent secondary infections, and promote healing in compromised skin. Originally developed by SMG Pharmaceuticals, the product is marketed in the United States by EPI Health.

Brand names: Bensal HP
Other names: benzoic acid + salicylic acid

Beyond the preview

Go deeper on Bensal HP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bensal HP.

Explore the full profile